Redcare Pharmacy lifts 2026 guidance: Redcare Pharmacy stock gains 3.19 percent

Redcare Pharmacy (ISIN NL0012044747) was trading at EUR 74.50 at Lang & Schwarz on October 15, 2026, at 10:38 a.m. CEST, up 3.19 percent versus the Xetra close of October 14, 2026, at EUR 72.20. The company had raised its full-year 2026 revenue growth guidance to 16 to 18 percent on September 28, 2026, according to Redcare Pharmacy.

Guidance points to stronger Rx demand

The revised outlook was the second increase during 2026. German prescription revenue is now expected at EUR 730 million to EUR 760 million for the full year, compared with EUR 680 million to EUR 720 million previously. Preliminary German prescription revenue grew 56.00 percent year over year in the third quarter, while September growth reached 51.00 percent.

The company kept its adjusted EBITDA margin guidance at 2.50 percent to 3.00 percent for 2026. That unchanged margin range is the key counterweight to the stronger sales outlook because the upcoming report must show whether prescription growth is translating into operating leverage.

Three milestones shaped the year

On July 30, 2026, Redcare reported second-quarter revenue of EUR 853.50 million, up 20.00 percent from the prior-year quarter, while net income was EUR 4.70 million, down 50.00 percent, according to Simply Wall St. On September 9, 2026, the company discussed the PoPP digital prescription framework, including a planned CardLink extension through March 2028. On September 28, 2026, Redcare raised total revenue growth guidance to 16 to 18 percent and German prescription revenue guidance to EUR 730 million to EUR 760 million, as stated in its release.

What does the growth mean for margins?

The answer depends on the mix of prescription and non-prescription sales. Redcare said non-prescription growth guidance remained 10 to 12 percent, while the adjusted EBITDA margin stayed at 2.50 percent to 3.00 percent for 2026. Deutsche Bank Research later raised its price target from EUR 103.00 to EUR 104.00 and kept its recommendation, according to Borse Express.

Next reporting dates are set

Redcare will publish its third-quarter 2026 interim statement and hold its quarterly conference call on October 29, 2026. Its 2026 annual report is scheduled for March 4, 2027, according to the investor-relations release. The October report will provide the next detailed test of the upgraded sales outlook and the unchanged margin range.

Stock remains below its yearly high

The EUR 74.50 reference price is EUR 15.00 below the 52-week high of EUR 89.50 and EUR 44.30 above the 52-week low of EUR 30.20, both as of October 15, 2026. Market capitalization stood at EUR 1.5 billion on the same date.

Redcare Pharmacy stock was trading at EUR 74.50 at Lang & Schwarz on October 15, 2026, at 10:38 a.m. CEST, 3.19 percent above the Xetra close of October 14, 2026, at EUR 72.20. The further course of trading is shown by the continuously updated real-time quote of Redcare Pharmacy stock.

Market context: Market report SDAX.

More news and analyses on Redcare Pharmacy stock